Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jun 15;101(12):2693–2701. doi: 10.1172/JCI549

Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency.

N Novoradovskaya 1, J Lee 1, Z X Yu 1, V J Ferrans 1, M Brantly 1
PMCID: PMC508860  PMID: 9637703

Abstract

The mutant Z form of alpha1-antitrypsin (alpha1AT) is responsible for > 95% of all individuals with alpha1AT deficiency, an important inherited cause of emphysema and liver disease. Since secreted Z alpha1AT is a functional antiprotease, we hypothesized that interrupting catabolism of retained Z alpha1AT might increase its transport out of cells, causing an increase in extracellular protease protection. Both the protein translation inhibitor cycloheximide and the specific inhibitor of proteasome function, lactacystin, prevented intracellular degradation of Z alpha1AT. Moreover, this inhibition of degradation was associated with partial restoration of Z alpha1AT vesicular transport. This effect was observed in a model system of transfected CHO cells as well as in human alveolar macrophages synthesizing Z alpha1AT. This study supports the hypothesis that altering the intracellular fate of a mutant protein may be an option in the treatment of diseases associated with misfolded but potentially functional proteins.

Full Text

The Full Text of this article is available as a PDF (3.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blank C. A., Brantly M. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann Allergy. 1994 Feb;72(2):105–122. [PubMed] [Google Scholar]
  2. Brantly M., Courtney M., Crystal R. G. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. Science. 1988 Dec 23;242(4886):1700–1702. doi: 10.1126/science.2904702. [DOI] [PubMed] [Google Scholar]
  3. Brantly M., Lee J. H., Hildesheim J., Uhm C. S., Prakash U. B., Staats B. A., Crystal R. G., Hildeshiem J. alpha1-antitrypsin gene mutation hot spot associated with the formation of a retained and degraded null variant [corrected; erratum to be published]. Am J Respir Cell Mol Biol. 1997 Mar;16(3):225–231. doi: 10.1165/ajrcmb.16.3.9070606. [DOI] [PubMed] [Google Scholar]
  4. Brodbeck R. M., Brown J. L. Secretion of alpha-1-proteinase inhibitor requires an almost full length molecule. J Biol Chem. 1992 Jan 5;267(1):294–297. [PubMed] [Google Scholar]
  5. Choudhury P., Liu Y., Bick R. J., Sifers R. N. Intracellular association between UDP-glucose:glycoprotein glucosyltransferase and an incompletely folded variant of alpha1-antitrypsin. J Biol Chem. 1997 May 16;272(20):13446–13451. doi: 10.1074/jbc.272.20.13446. [DOI] [PubMed] [Google Scholar]
  6. Ciccarelli E., Alonso M. A., Cresteil D., Bollen A., Jacobs P., Alvarez F. Intracellular retention and degradation of human mutant variant of a alpha 1-antitrypsin in stably transfected Chinese hamster ovary cell lines. Eur J Biochem. 1993 Apr 1;213(1):271–276. doi: 10.1111/j.1432-1033.1993.tb17759.x. [DOI] [PubMed] [Google Scholar]
  7. Fenteany G., Standaert R. F., Lane W. S., Choi S., Corey E. J., Schreiber S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995 May 5;268(5211):726–731. doi: 10.1126/science.7732382. [DOI] [PubMed] [Google Scholar]
  8. Goldberg A. L. Functions of the proteasome: the lysis at the end of the tunnel. Science. 1995 Apr 28;268(5210):522–523. doi: 10.1126/science.7725095. [DOI] [PubMed] [Google Scholar]
  9. Goldberg A. L., St John A. C. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem. 1976;45:747–803. doi: 10.1146/annurev.bi.45.070176.003531. [DOI] [PubMed] [Google Scholar]
  10. Gunderson K. L., Kopito R. R. Conformational states of CFTR associated with channel gating: the role ATP binding and hydrolysis. Cell. 1995 Jul 28;82(2):231–239. doi: 10.1016/0092-8674(95)90310-0. [DOI] [PubMed] [Google Scholar]
  11. Hammond C., Helenius A. Quality control in the secretory pathway. Curr Opin Cell Biol. 1995 Aug;7(4):523–529. doi: 10.1016/0955-0674(95)80009-3. [DOI] [PubMed] [Google Scholar]
  12. Jensen T. J., Loo M. A., Pind S., Williams D. B., Goldberg A. L., Riordan J. R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell. 1995 Oct 6;83(1):129–135. doi: 10.1016/0092-8674(95)90241-4. [DOI] [PubMed] [Google Scholar]
  13. Klausner R. D., Sitia R. Protein degradation in the endoplasmic reticulum. Cell. 1990 Aug 24;62(4):611–614. doi: 10.1016/0092-8674(90)90104-m. [DOI] [PubMed] [Google Scholar]
  14. Laubach V. E., Ryan W. J., Brantly M. Characterization of a human alpha 1-antitrypsin null allele involving aberrant mRNA splicing. Hum Mol Genet. 1993 Jul;2(7):1001–1005. doi: 10.1093/hmg/2.7.1001. [DOI] [PubMed] [Google Scholar]
  15. Le A., Ferrell G. A., Dishon D. S., Le Q. Q., Sifers R. N. Soluble aggregates of the human PiZ alpha 1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis. J Biol Chem. 1992 Jan 15;267(2):1072–1080. [PubMed] [Google Scholar]
  16. Le A., Graham K. S., Sifers R. N. Intracellular degradation of the transport-impaired human PiZ alpha 1-antitrypsin variant. Biochemical mapping of the degradative event among compartments of the secretory pathway. J Biol Chem. 1990 Aug 15;265(23):14001–14007. [PubMed] [Google Scholar]
  17. Le A., Steiner J. L., Ferrell G. A., Shaker J. C., Sifers R. N. Association between calnexin and a secretion-incompetent variant of human alpha 1-antitrypsin. J Biol Chem. 1994 Mar 11;269(10):7514–7519. [PubMed] [Google Scholar]
  18. Lippincott-Schwartz J., Bonifacino J. S., Yuan L. C., Klausner R. D. Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell. 1988 Jul 15;54(2):209–220. doi: 10.1016/0092-8674(88)90553-3. [DOI] [PubMed] [Google Scholar]
  19. Lippincott-Schwartz J., Yuan L. C., Bonifacino J. S., Klausner R. D. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell. 1989 Mar 10;56(5):801–813. doi: 10.1016/0092-8674(89)90685-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Liu Y., Choudhury P., Cabral C. M., Sifers R. N. Intracellular disposal of incompletely folded human alpha1-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosaccharides. J Biol Chem. 1997 Mar 21;272(12):7946–7951. doi: 10.1074/jbc.272.12.7946. [DOI] [PubMed] [Google Scholar]
  21. Lohmeyer J., Friedrich J., Rosseau S., Pralle H., Seeger W. Multiparameter flow cytometric analysis of inflammatory cells contained in bronchoalveolar lavage fluid. J Immunol Methods. 1994 Jun 3;172(1):59–70. doi: 10.1016/0022-1759(94)90378-6. [DOI] [PubMed] [Google Scholar]
  22. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  23. Lomas D. A. Loop-sheet polymerization: the structural basis of Z alpha 1-antitrypsin accumulation in the liver. Clin Sci (Lond) 1994 May;86(5):489–495. doi: 10.1042/cs0860489. [DOI] [PubMed] [Google Scholar]
  24. McCracken A. A., Kruse K. B., Brown J. L. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342. Mol Cell Biol. 1989 Apr;9(4):1406–1414. doi: 10.1128/mcb.9.4.1406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ogushi F., Fells G. A., Hubbard R. C., Straus S. D., Crystal R. G. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987 Nov;80(5):1366–1374. doi: 10.1172/JCI113214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ou W. J., Cameron P. H., Thomas D. Y., Bergeron J. J. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature. 1993 Aug 26;364(6440):771–776. doi: 10.1038/364771a0. [DOI] [PubMed] [Google Scholar]
  27. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773–785. doi: 10.1016/s0092-8674(94)90482-0. [DOI] [PubMed] [Google Scholar]
  28. Perlmutter D. H., Cole F. S., Kilbridge P., Rossing T. H., Colten H. R. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci U S A. 1985 Feb;82(3):795–799. doi: 10.1073/pnas.82.3.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Perlmutter D. H., Kay R. M., Cole F. S., Rossing T. H., Van Thiel D., Colten H. R. A selective defect in secretion of alpha 1-proteinase inhibitor PiZZ demonstrated in surrogate and primary extrahepatic cell culture. Trans Assoc Am Physicians. 1985;98:47–54. [PubMed] [Google Scholar]
  30. Perlmutter D. H., Kay R. M., Cole F. S., Rossing T. H., Van Thiel D., Colten H. R. The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci U S A. 1985 Oct;82(20):6918–6921. doi: 10.1073/pnas.82.20.6918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Qu D., Teckman J. H., Omura S., Perlmutter D. H. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996 Sep 13;271(37):22791–22795. doi: 10.1074/jbc.271.37.22791. [DOI] [PubMed] [Google Scholar]
  32. Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761–771. doi: 10.1016/s0092-8674(94)90462-6. [DOI] [PubMed] [Google Scholar]
  33. Sato S., Ward C. L., Krouse M. E., Wine J. J., Kopito R. R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem. 1996 Jan 12;271(2):635–638. doi: 10.1074/jbc.271.2.635. [DOI] [PubMed] [Google Scholar]
  34. Sawada H., Muto K., Fujimuro M., Akaishi T., Sawada M. T., Yokosawa H., Goldberg A. L. Different ratios in 20 S proteasomes and regulatory subunit complexes in two isoforms of the 26 S proteasome purified from rabbit skeletal muscle. FEBS Lett. 1993 Dec 6;335(2):207–212. doi: 10.1016/0014-5793(93)80731-9. [DOI] [PubMed] [Google Scholar]
  35. Sifers R. N. Defective protein folding as a cause of disease. Nat Struct Biol. 1995 May;2(5):355–357. doi: 10.1038/nsb0595-355. [DOI] [PubMed] [Google Scholar]
  36. Sifers R. N., Finegold M. J., Woo S. L. Molecular biology and genetics of alpha 1-antitrypsin deficiency. Semin Liver Dis. 1992 Aug;12(3):301–310. doi: 10.1055/s-2008-1040399. [DOI] [PubMed] [Google Scholar]
  37. Sifers R. N. Protein transport. Z and the insoluble answer. Nature. 1992 Jun 18;357(6379):541–542. doi: 10.1038/357541a0. [DOI] [PubMed] [Google Scholar]
  38. Thomas P. J., Qu B. H., Pedersen P. L. Defective protein folding as a basis of human disease. Trends Biochem Sci. 1995 Nov;20(11):456–459. doi: 10.1016/s0968-0004(00)89100-8. [DOI] [PubMed] [Google Scholar]
  39. Ward C. L., Kopito R. R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem. 1994 Oct 14;269(41):25710–25718. [PubMed] [Google Scholar]
  40. Yu M. H., Lee K. N., Kim J. The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. Nat Struct Biol. 1995 May;2(5):363–367. doi: 10.1038/nsb0595-363. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES